Group C streptococci isolated from throat swabs: a laboratory and clinical study

R F M Lewis, A E Balfour

Abstract
Aims—To determine the prevalence of \( \beta \) haemolytic, Lancefield group C streptococci in throat swabs taken in routine clinical practice, and correlate the species identified with presenting clinical features.

Methods—One year, laboratory based prospective study, using a questionnaire to elicit clinical information.

Results—4.4% of throat swabs yielded group C streptococci, of which 38% belonged to \( S \) equisimilis and 53% to \( S \) anginosus-milleri group (SAM). Pyrexia was more common in patients with \( S \) equisimilis, but other clinical features did not differ significantly between the two groups. No \( S \) zooepidemicus was isolated.

Conclusions—Species identification of group C streptococci from throat swabs does not appear to be clinically useful in this patient population. However, the prevalence and spectrum of organisms is similar to that reported in N America, where studies suggest a possible role in some cases of severe pharyngitis. Observational studies such as this lack power to resolve the issue of pathogenicity, for which a placebo controlled trial of antibiotic treatment is ideally required.

Keywords: pharyngitis; group C streptococcus

The role of group C streptococci as a cause of sore throat has been debated at least since 1947, when a prospective study of over 3000 US army recruits admitted to hospital with respiratory tract infections revealed seven with group C streptococci. None of the 65 positive throat swabs of 1493 received (4.4%) yielded group C streptococci. None of the 65 positive swabs were from hospital inpatients. Most were from young adults, with only one patient under the age of 15 years. Four of the 65 patients were found to have another microbiological cause for their sore throat (oral candidiasis in one,
rubella in one, positive glandular fever screening test in two), and were excluded from analysis. A further three cases were excluded because no clinical data could be obtained.

Twenty two (38%) of the isolates from the remaining 58 patients were identified as *Streptococcus equisimilis*, one as *S sanguis*, and 31 (53%) as *S anginosus-milleri* group. Four strains could not be speciated with certainty from their biochemical profile, and these were also excluded from analysis.

The clinical features in the 54 evaluable patients are summarised in table 1. Thirty three of the patients (63%) were prescribed antibiotics empirically at presentation, a further seven (13%) at a subsequent consultation, and 13 (25%) received no antibiotics. Data were unavailable for one patient. There was no significant difference between patients with Group C *S equisimilis* and those with Group C *S anginosus-milleri* group with respect to cervical lymphadenopathy, throat exudate, or the prescribing of empirical antibiotics at first consultation. However, pyrexia was recorded by the doctor in eight of 19 patients with *S equisimilis* compared with four of 27 with *S anginosus-milleri* group (p = 0.05 by Fisher’s exact test).

### Discussion

Faced with a β haemolytic streptococcus from a throat swab, which turns out to belong to Lancefield group C, how should the medical microbiology laboratory proceed? Historically, all attention has been focused on the recognition of group A streptococci, so that treatment can be instituted to prevent the serious sequelae of rheumatic fever and post-streptococcal infection with the predominant species of this group, *S pyogenes*. The widespread introduction of susceptibility to a bacitracin disc as a screening test for the presence of *S pyogenes* in throat swabs led to group C species (which are mostly bacitracin resistant) being ignored. Bacitracin susceptibility testing fell from favour as a screening test once latex agglutination methods had much simplified the procedure of determining the Lancefield group, but it had already been noted in 1969 that an animal species of bacitracin resistant, large colony group C streptococcus could cause sore throat, septicaemia, and post-streptococcal nephritis in humans. So far the small number of reported cases of infection with this organism, since named *Streptococcus zooepidemicus*, has been confined to those who have either been in close contact with farm animals, or have drunk unpasteurised milk. Among over 3000 patients with sore throat included in three recent North American series, only a single case of *S zooepidemicus* was detected, and we have found none in the present study.

The other large colony group C streptococci which have been isolated from the human body belong to *Streptococcus equisimilis*, a species which also properly includes strains of Lancefield group G. Although this species has been described as a commensal in the pharynx, gut, and female genital tract, invasive disease is also well documented, and outbreaks have been reported from single strains (as judged by T protein typing), in one instance causing postpartum infection in a maternity unit, and in other instances food borne infection. Those strains from cases of overt infection which have been studied resemble *S pyogenes* in expressing an M protein which confers resistance to phagocytosis. Some of them also produce extracellular enzymes common to *S pyogenes* such as streptolysin O and hyaluronidase, and invasive infection has been accompanied by antibody responses to these proteins. The extent to which these properties are shared by commensal *S equisimilis* strains is at present unknown.

The SAM group of streptococci are variable in their polysaccharide antigens, and fall genetically into three groups, for which the species names *S constellatus*, *S anginosus*, and *S intermedius* have been proposed. Outbreaks of all three genotypes have been isolated from purulent lesions at a variety of body sites; possible pathogenic mechanisms are reviewed by Whitworth.

### Table 2 Comparative data on group C streptococci from throat cultures in cases of pharyngitis

<table>
<thead>
<tr>
<th>Reference</th>
<th>Year of publication</th>
<th>Study setting</th>
<th>Patients with pharyngitis</th>
<th>Control patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>n</td>
<td>S equisimilis isolated (%)</td>
</tr>
<tr>
<td>7</td>
<td>1990</td>
<td>Paediatric outpatient clinic, USA</td>
<td>1730</td>
<td>0.7</td>
</tr>
<tr>
<td>8</td>
<td>1991</td>
<td>Paediatric outpatient clinic, USA</td>
<td>255</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>1993</td>
<td>College students, USA</td>
<td>1480</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>1997</td>
<td>College students, USA</td>
<td>265</td>
<td>11</td>
</tr>
<tr>
<td>Present study</td>
<td>General practice, UK</td>
<td>1486</td>
<td>1.5</td>
<td>2.1</td>
</tr>
</tbody>
</table>

ND, no data; SAM, *Streptococcus anginosus-milleri*. 

The widespread introduction of susceptibility to a bacitracin disc as a screening test for the presence of *S pyogenes* in throat swabs led to group C species (which are mostly bacitracin resistant) being ignored. Bacitracin susceptibility testing fell from favour as a screening test once latex agglutination methods had much simplified the procedure of determining the Lancefield group, but it had already been noted in 1969 that an animal species of bacitracin resistant, large colony group C streptococcus could cause sore throat, septicaemia, and post-streptococcal nephritis in humans. So far the small number of reported cases of infection with this organism, since named *Streptococcus zooepidemicus*, has been confined to those who have either been in close contact with farm animals, or have drunk unpasteurised milk. Among over 3000 patients with sore throat included in three recent North American series, only a single case of *S zooepidemicus* was detected, and we have found none in the present study.
We have found group C streptococci from the throats of patients with pharyngitis to belong in roughly equal proportions to either S. equisimilis or the S. anginosus-milleri group (SAM). This may be compared with the results of recent North American studies (table 2), which with one exception do not lend any support to the hypothesis that either organism is responsible for sore throat. The exception is the 1997 study by Turner and colleagues, which differed in including only those patients (about a quarter of those who had throat swabs taken) who had definitive clinical evidence of pharyngeal exudate. Unfortunately, the identification methods used for group C streptococci in this paper, while distinguishing SAM group C from S. equisimilis, do not distinguish S. equisimilis from S. zooepidemicus. Nevertheless Turner’s study suggests that there may be a subgroup of patients with severe pharyngitis where either SAM group C or S. equisimilis have a causal role, but that most studies to date suffer from the dilutional effect of too many cases of mild pharyngitis in which group C streptococci, though present, have no such role. The logical next step from these case–control studies is a prospective, placebo controlled trial of penicillin treatment for patients with exudative pharyngitis whose throat swabs yield S. equisimilis or SAM group C. Given the low prevalence of this situation, and the probable need to stratify patients by age and quantity of organisms isolated, this is not a light undertaking.

Pending the outcome of such a study, it seems to us inappropriate for the laboratory to report S. equisimilis or SAM group C from throat swabs at present, particularly at a time when the value of giving antibiotics at all in cases of sore throat is being increasingly doubted. At present, the only confirmed throat pathogen among the group C streptococci is S. zooepidemicus, which may be detected by its combination of β-glucuronidase activity, lactose and sorbitol fermentation, and failure to ferment trehalose. In view of its rarity, examination even for this organism may best be confined to cases where infection “....is severe, invasive or followed by post-streptococcal glomerulonephritis, when there seems to be a link with animals, or when clusters occur,” as suggested by those who first described the organism. If future trials of antibiotic treatment do incriminate either of the two common species of group C streptococci, it is worth noting that these four tests (β-glucuronidase, lactose, sorbitol, and trehalose) will also identify both SAM and S. equisimilis.